David Weingeist

Director Johnson & Johnson

David is the Global Dx Development Leader for the Bladder Cancer Team at Johnson & Johnson Innovative Medicine, where he is responsible for development of global diagnostic solutions in support of the bladder cancer precision medicine portfolio.

David received a bachelor’s degree in Chemical Engineering from Washington University in St. Louis and a master’s degree in BioScience Enterprise from Cambridge University. He earned his doctorate in Bioengineering from the Massachusetts Institute of Technology, where he conducted his graduate research developing a novel assay to measure DNA damage and repair kinetics. His professional experience prior to Johnson & Johnson Innovative Medicine includes seven years in life science strategy consulting with a focus in precision medicine and another five years at Roche Pharmaceuticals (Genentech and Foundation Medicine) in the personalized healthcare, global product strategy organization.

Seminars

Monday 22nd September 2025
Innovative Diagnostic Solutions: Maximizing Opportunities in Bladder Cancer Treatment
9:50 am
  • Reviewing strategies to address tissue insufficiency
  • Showcasing urine based liquid biopsy for patient selection and monitoring
  • Exploring a histopathology-based AI algorithm for FGFR detection
Tuesday 23rd September 2025
Panel Discussion: Navigating the Common Pitfalls in Digital Pathology to Streamline CDx Development & Adoption
9:50 am
  • What are the key strategies to overcome barriers to widespread adoption of digital pathology? And how can organizations build the necessary infrastructure to support digital pathology at scale?
  • What are the commercial challenges facing digital pathology as a companion diagnostic and how can companies address these obstacles?
  • What are the current regulatory challenges in getting digital pathology technologies approved for use as CDx, and how can these be addressed moving forward?
David Weingeist